UnknownPHASE1, PHASE2NCT04744532

iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kyoto University
Principal Investigator
Haruhisa Inoue
Kyoto University
Intervention
Bosutinib (Phase 1 part)(drug)
Enrollment
49 enrolled
Eligibility
20-75 years · All sexes
Timeline
20192024

Study locations (7)

Collaborators

Tokushima University · Kitasato University · Tottori University · Nara Medical University · Toho University · Hiroshima University · Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04744532 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials